These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18586683)

  • 1. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.
    Walenga JM; Drenth AF; Mayuga M; Hoppensteadt DA; Prechel M; Harder S; Watanabe H; Osakabe M; Breddin HK
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):325-31. PubMed ID: 18586683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
    Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
    Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
    Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral anticoagulation with vitamin K antagonists].
    Alberio L
    Ther Umsch; 2003 Jan; 60(1):5-9. PubMed ID: 12638470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
    Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
    J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
    Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
    J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.
    van Geest-Daalderop JH; Hutten BA; Péquériaux NC; Haas FJ; Levi M; Sturk A
    Thromb Haemost; 2007 Oct; 98(4):738-46. PubMed ID: 17938796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction.
    Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):288-93. PubMed ID: 18469550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation laboratory testing in patients treated with argatroban.
    Walenga JM; Fasanella AR; Iqbal O; Hoppensteadt DA; Ahmad S; Wallis DE; Bakhos M
    Semin Thromb Hemost; 1999; 25 Suppl 1():61-6. PubMed ID: 10357154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenprocoumon and acenocoumarol treatment in paediatric patients.
    Spoor N; Smiers FJ; van der Meer FJ; Hutten BA; van Ommen CH
    Thromb Haemost; 2012 Dec; 108(6):1238-41. PubMed ID: 23014894
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
    van den Besselaar AM; Biedermann JS; Kruip MJ
    Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
    Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
    Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.
    Austin JH; Stearns CR; Winkler AM; Paciullo CA
    Pharmacotherapy; 2012 Jun; 32(6):493-501. PubMed ID: 22511112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
    Sheth SB; DiCicco RA; Hursting MJ; Montague T; Jorkasky DK
    Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Body Weight on Dose of Vitamin K Antagonists.
    Self TH; Wallace JL; Sakaan S; Sands CW
    South Med J; 2015 Oct; 108(10):637-43. PubMed ID: 26437201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A study of the dosage of argatroban for anticoagulation effect in the patients undergoing high volume hemofiltration].
    Wang Y; Chen XM; Sun XF; Xiang J
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Apr; 21(4):240-2. PubMed ID: 19374795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
    Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.